Cempra, Inc. to Present at Piper Jaffray 25th Annual Healthcare Conference and
Oppenheimer 24th Annual Healthcare Conference
CHAPEL HILL, N.C., Dec. 2, 2013 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP)
today announced that Prabhavathi Fernandes, Ph.D., chief executive officer of
Cempra, will present at the Piper Jaffray 25^th Annual Healthcare Conference
at 2:30 p.m. EST, Wednesday, Dec. 4, at The New York Palace Hotel, and at the
Oppenheimer 24^th Annual Healthcare Conference at 3:55 p.m. EST, Wednesday,
Dec. 11, at The Crowne Plaza Hotel in New York City. Dr. Fernandes will
discuss the company's two differentiated antibiotics, solithromycin (CEM-101)
for community-acquired bacterial pneumonia and TAKSTA (CEM-102 or fusidic
acid) for the chronic, oral treatment of Gram-positive pathogens including
methicillin-resistant S. aureus (MRSA) in prosthetic joint infections.
About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a late clinical-stage pharmaceutical company
focused on developing antibiotics to treat critical bacterial infections in
patients in both acute and primary care settings. Cempra's two lead product
candidates are currently in advanced clinical development.Solithromycin
(CEM-101) is in two Phase 3 clinical trial for community-acquired bacterial
pneumonia (CABP) and is licensed to strategic commercial partner Toyama
Chemical Co., Ltd., a subsidiary of FUJIFILM Holdings Corporation, for certain
exclusive rights in Japan.TAKSTA™ (CEM-102) is Cempra's second product
candidate currently in a Phase 2 clinical trial for prosthetic joint
infections. TAKSTA was recently granted orphan drug designation for this
indication. Both product candidates seek to address the need for new
treatments targeting drug-resistant bacterial infections in the hospital and
in the community. The company also intends to use its series of proprietary
lead compounds from its novel macrolide library for uses such as the treatment
of chronic inflammatory diseases, endocrine diseases and gastric motility
disorders. Additional information about Cempra can be found at www.cempra.com.
Please Note: This press release contains forward-looking statements regarding
future events. These statements are just predictions and are subject to risks
and uncertainties that could cause the actual events or results to differ
materially. These risks and uncertainties include, among others: the results,
timing, costs and regulatory review of our studies and clinical trials; the
results of studies of our product candidates conducted by others; our need to
obtain additional funding and our ability to obtain future funding on
acceptable terms; our anticipated capital expenditures and our estimates
regarding our capital requirements; our ability to obtain FDA approval of our
product candidates; our dependence on the success of solithromycin and Taksta;
the possible impairment of, or inability to obtain, intellectual property
rights and the costs of obtaining such rights from third parties; and
innovation by our competitors. The reader is referred to the documents that we
file from time to time with the Securities and Exchange Commission.
CONTACT: Investor and Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
Russo Partners, LLC
Press spacebar to pause and continue. Press esc to stop.